Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CNS start-up Addex gets CHF40mm with Series C round

Executive Summary

Swiss neurological disease start-up Addex Pharmaceuticals SA, which is researching allosteric modulators of GPCR targets, raised CHF40mm ($32mm) in its Series C financing. The round was led by new backer SR One and included fellow new investor Roche Venture Fund and existing shareholders Sofinnova Partners, Index Ventures, TVM Capital, PolyTechnos Venture-Partners, Bio*One Capital, Renaissance, and Varuma. A member of SR One will take a seat on the company's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies